Vimian Group AB

VIMIAN · Nasdaq Stockholm · Healthcare

35.20SEK −1.3%last day

Price as of 2 October 2026

The price over the past year, with dividends: +23.6%

Performance

1 month

+1.7%

1 year

+23.6%

3 years, per year

+14.5%

5 years, per year

−15.7%

Largest fall, 3 years

−82.9%

Below the peak now

−70.0%

Volatility, 1 year

33.7%

Return with dividends reinvested.

Key figures

P/E

44.1

P/B

2.2

Dividend yield

0.0%

Return on equity

+5.0%

Net margin

+8.2%

Market value

1.9 bn USD

Quality, value and trend

Where Vimian Group stands against every Nordic stock today. 100 is best.

Quality59

Profitability and a sound balance sheet over time. Better than 59% of Nordic stocks.

Value32

The price measured against earnings, assets and cash flow. Better than 32% of Nordic stocks.

Trend87

The price development over the past year. Better than 87% of Nordic stocks.

Combined65

Quality, value and trend together. Better than 65% of Nordic stocks.

About Vimian Group

Vimian Group AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 1,300 employees.

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis